MyoKardia, Inc. is pioneering a precision medicine approach to treating genetic heart disease.

By combining leading-edge cardiovascular genetics with recent advances in heart muscle biochemistry, MyoKardia seeks to revolutionize the treatment of cardiomyopathies and make a meaningful difference in the lives of the millions of people suffering from cardiovascular diseases.

Learn More

News & Events

09.17.14
Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease
Link

05.14.14
MyoKardia Announces Launch of SHaRe Patient Registry for Genetic Heart Disease in Collaboration with World-Leading Cardiovascular Patient Care Centers
Link

11.25.13
MyoKardia Appoints Biotech Veteran Mark L. Perry to Board of Directors
Link